NEW YORK CITY and NEW ORLEANS, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 17, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cytokinetics, Incorporated (NasdaqGS: CYTK), if they purchased or otherwise acquired the Company’s securities between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). This action is p ...

NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cytokinetics, Incorporated ("Cytokinetics" or the "Company") (NASDAQ: CYTK) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cytokinetics investors who were adversely affected by alleged securities fraud between December 27, 2023 and May 6, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/cytokine ...

NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cytokinetics, Incorporated ("Cytokinetics" or the "Company") (NASDAQ: CYTK) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cytokinetics investors who were adversely affected by alleged securities fraud between December 27, 2023 and May 6, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/cytokine ...

SAN DIEGO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Cytokinetics, Inc. (NASDAQ: CYTK) securities between December 27, 2023 and May 6, 2025. Cytokinetics is a biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performan ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Cytokinetics (CYTK) To Contact Him Directly To Discuss Their Options If you purchased or acquired common stock in Cytokinetics between December 27, 2023 and May 6, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- What’s H ...

LOS ANGELES, Sept. 18, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Cytokinetics, Inc., (“Cytokinetics” or the "Company") (NASDAQ: CYTK) investors of a class action on behalf of investors that bought securities between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). Cytokinetic investors have until November 17, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss the ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Cytokinetics To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Cytokinetics between December 27, 2023 and May 6, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Sept. 18, 2025 ...

We recently published 10 Big Names Investors Are Dumping. Cytokinetics, Inc. (NASDAQ:CYTK) is one of the worst performers on Wednesday. Shares of Cytokinetics dropped by 4.42 percent on Wednesday to end at $47.56 apiece after upsizing its senior convertible notes issuance to $650 million. In a statement, Cytokinetics, Inc. (NASDAQ:CYTK) said it aimed to raise $650 million from the offer, an increase from the $550 million targeted initially. The notes carry a yield rate of 1.75 percent until 2031 and will ...

NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities who purchased or otherwise acquired Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) securities between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). The Complaint alleges that Defendants made materially false and mi ...

ATLANTA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK). The lawsuit alleges Defendants represented that Cytokinetics expected approval from the U.S. Food and Drug Administration ("FDA") for its NDA for aficamten in the second half of 2025, based on a September 26, 2025 PDUFA date, and failed to disclose material risks related to the Company's failure to submit a Risk Evaluation and Miti ...